1. Perioperative immune checkpoint inhibitor therapy for gastric and gastroesophageal junction cancers: a review of current approaches and future perspectives

   • Daisuke Takahari
   • Izuma Nakayama

   Invited Review Article 28 July 2023 Pages: 1431 - 1441

   

2. Immune checkpoint inhibitor therapy in neoadjuvant and adjuvant treatment for cancer: A paradigm shift in the treatment of resectable gastrointestinal cancer 3)A paradigm shift in the treatment of colorectal cancer

   • Kotoe Oshima
   • Kentaro Yamazaki

   Invited Review Article 05 September 2023 Pages: 1442 - 1450

3. Oncology drug lag in Japan: has it improved over the last decade?

   • Yoshifumi Tachibana
   • Mamoru Narukawa

   Original Article 10 August 2023 Pages: 1451 - 1460

   

4. The diagnostic potential of two exosome-derived circRNAs for papillary thyroid cancer

   • Lei Dai
   • Weibin Hu
   • Xiaodan Meng

   Original Article 11 August 2023 Pages: 1461 - 1474

   

5. Circ_0000419 acts as a tumor suppressor in gastric cancer development via regulating miR-300/RGMB axis

   • Jiajun Lu
   • Yuan Zhou
   • Guangjian Dou

   Original Article 20 July 2023 Pages: 1475 - 1485

   

6. Correction to: Circ_0000419 acts as a tumor suppressor in gastric cancer development via regulating miR‑300/RGMB axis

   • Jiajun Lu
   • Yuan Zhou
   • Guangjian Dou

   Correction 13 September 2023 Pages: 1486 - 1486

7. Expression of SMARCA2 and SMARCA4 in gastric adenocarcinoma and construction of a nomogram prognostic model

   • Zhenkun Zhang
   • Qiujing Li
   • Shukun Zhang

   Original Article 27 August 2023 Pages: 1487 - 1500

   

8. Meta-analysis of three randomized trials of capecitabine plus cisplatin (XP) versus S-1 plus cisplatin (SP) as first-line treatment for advanced gastric cancer

   • Kazuhiro Nishikawa
   • Hisato Kawakami
   • for HERBIS-2, HERBIS-4A, XParTS I. I. study investigators

   Original Article 27 August 2023 Pages: 1501 - 1510

   

9. Impact of Smad4 and p53 mutations on the prognosis of patients with pancreatic ductal adenocarcinoma undergoing chemotherapy

   • Ken Kamata
   • Mamoru Takenaka
   • Masatoshi Kudo

   Original Article 18 August 2023 Pages: 1511 - 1519

   

10. Effect of duration of adjuvant chemotherapy with S-1 (6 versus 12 months) for resected pancreatic cancer: the multicenter clinical randomized phase II postoperative adjuvant chemotherapy S-1 (PACS-1) trial

    • Hiroto Kayashima
    • Shinji Itoh
    • Tomoharu Yoshizumi

    Original Article 08 August 2023 Pages: 1520 - 1529

    

11. Real clinical outcomes of nivolumab plus ipilimumab for renal cell carcinoma in patients over 75 years old

    • Mizuki Kobayashi
    • Kazuyuki Numakura
    • Tomonori Habuchi

    Original Article 08 August 2023 Pages: 1530 - 1537

    

12. Preoperative prognostic model for localized and locally advanced renal cell carcinoma: Michinoku Japan Urological Cancer Study Group

    • Shigemitsu Horie
    • Sei Naito
    • Norihiko Tsuchiya

    Original Article 22 September 2023 Pages: 1538 - 1544

    

13. Superior detection of significant prostate cancer by transperineal prostate biopsy using MRI-transrectal ultrasound fusion image guidance over cognitive registration

    • Masaya Ito
    • Ichiro Yonese
    • Fumitaka Koga

    Original Article 22 August 2023 Pages: 1545 - 1553

    

14. Clinical availability and characteristics of multigene panel testing for recurrent/advanced gynecologic cancer

    • Shoko Kitazawa
    • Tatsuyuki Chiyoda
    • Daisuke Aoki

    Original Article 13 August 2023 Pages: 1554 - 1562

15. Advantages and limitations of estrogen replacement therapy on hypogonadal survivors of childhood cancer

    • Miwa Nakamura
    • Takashi Ohba
    • Eiji Kondoh

    Original Article 30 August 2023 Pages: 1563 - 1572